Sexual dysfunction ‐ not reported · participants with chronic prostatitis/chronic pelvic pain syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not reported · participants with chronic prostatitis/chronic pelvic pain syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depression and anxiety ‐ not reported · participants with chronic prostatitis/chronic pelvic pain syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Reduction in frequency and severity of drooling · Adults with Parkinson's disease and sialorrhea (drooling)
Type A botulinum toxin significantly reduced DSFS scores versus placebo (SMD -0.80, 95% CI -1.25 to -0.36; ungraded subgroup).
3 findings from 1 review
Adverse events (participants with >=1 adverse event) · Adults with Parkinson's disease and sialorrhea (drooling)
Type A botulinum toxin showed a borderline, non-significant increase in adverse events versus placebo (RD 0.10, 95% CI 0.00 to 0.21; ungraded subgroup).
3 findings from 1 review
Participant‐reported improvement in sialorrhea in the short term · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
Botulinum toxin injection showed no clear difference in participant‐reported improvement in sialorrhea in the short term… compared with placebo (low certainty).
1 finding from 1 review
Reduction in the amount of saliva production in the short term using an objective measure · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
1 finding from 1 review
Health‐related quality of life Assessed by: SeiQoL‐DW (higher scores mean better quality of life) · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
1 finding from 1 review
Adverse effects · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
Botulinum toxin injection may leads to lower adverse effects compared with placebo (low certainty).
1 finding from 1 review
Participant assessment of success by analysing scores and scales ‐ 4 weeks · glabellar lines
Summary of Findings Table ‐ AbobotulinumtoxinA 50U showed no clear difference in participant assessment success by analysing scores and scales ‐ 4… compared with onabotulinumtoxinA 20U (high certainty).
1 finding from 1 review
Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) · glabellar lines
Summary of Findings Table ‐ AbobotulinumtoxinA 50U showed no clear difference in major adverse events ‐ Any major adverse events (eyelid ptosis,… compared with onabotulinumtoxinA 20U (moderate certainty).
1 finding from 1 review
Physician assessment of success by analysing scores and scales ‐ 4 weeks (Validated tools, wrinkles and lines at maximum contraction) · glabellar lines
Summary of Findings Table ‐ AbobotulinumtoxinA 50U showed no clear difference in physician assessment of success by analysing scores and scales ‐ 4… compared with onabotulinumtoxinA 20U (high certainty).
1 finding from 1 review
Total adverse events · glabellar lines
Summary of Findings Table ‐ AbobotulinumtoxinA 50U showed no clear difference in total adverse events compared with onabotulinumtoxinA 20U (moderate certainty).
1 finding from 1 review
Duration of treatment effect ‐ not measured · glabellar lines
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participant global assessment of success Not measured · glabellar lines
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major adverse events · glabellar lines
It is very uncertain whether summary of Findings Table ‐ IncobotulinumtoxinA 24U changes major adverse events compared with onabotulinumtoxinA 24U (very low certainty).
1 finding from 1 review
Physician assessment of success by analysing scores and scales ‐ 4 weeks (Validated tools, wrinkles and lines at maximum contraction) · glabellar lines
Summary of Findings Table ‐ IncobotulinumtoxinA 24U showed no clear difference in physician assessment of success by analysing scores and scales ‐ 4… compared with onabotulinumtoxinA 24U (low certainty).
1 finding from 1 review
Total adverse events · glabellar lines
It is very uncertain whether summary of Findings Table ‐ IncobotulinumtoxinA 24U changes total adverse events compared with onabotulinumtoxinA 24U (very low certainty).
1 finding from 1 review
Duration of treatment effect ‐ not measured · glabellar lines
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement (greater than 50% of time spent) heel‐toe walking Measured by parents' perception of toe walking frequency more than 50% of the time. · children with ITW gait
It is very uncertain whether botulinum toxin plus conservative treatment changes improvement (greater than 50% of time spent) heel‐toe walking… compared with conservative treatment only (very low certainty).
1 finding from 1 review